Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Any Idea Why?...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by Zoomie1999on Mar 16, 2021 7:47am
226 Views
Post# 32805830

RE:RE:RE:RE:RE:Any Idea Why?...

RE:RE:RE:RE:RE:Any Idea Why?...

Optimism for the non-selective approach seems unlikely given concerns about overall performance of both Biogen's Aducanumab and Lilly's Donanemab.  I think door now wide open to finally try Promis' SELECTIVE targeting hypothesis via PMN-310.  Not sure this team can get that done. Therefore, partnership or sale of the "technology" to Biogen or Lilly may be our best way out of "penny stock" land.

Not sure if withdrawal of November 2020 prospectus means positive or negative outlook but it points to potential material change one way or the other.  Got back it yesterday only to watch it slide yet again - arghh.

https://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-alzheimers-drug-donanemab-data-underwhelms-2021-3-1030204307


 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities